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Acetaldehyde (ACD), the first metabolite of ethanol (EtOH), has been implicated in
several actions of alcohol, including its reinforcing effects. Previously considered an
aversive compound, ACD was useful in alcoholic’s pharmacological treatment aimed at
discouraging alcohol drinking. However, it has recently been shown that EtOH-derived
ACD is necessary for EtOH-induced place preference and self-administration, thereby
suggesting a possible involvement of ACD in EtOH motivational properties. In addition,
EtOH-stimulating properties on DA neurons are prevented by pharmacological blockade
of local catalase H2O2 system, the main metabolic step for biotransformation of EtOH
into ACD within the central nervous system. It was further shown that pretreatment
with thiol compounds, like L-Cysteine or D-Penicillamine, reduced EtOH and ACD-induced
motivational effects, in fact preventing self-administration of both EtOH and ACD, thus
suggesting a possible role for ACD as a biomarker useful in evaluating potential innovative
treatments of alcohol abuse. These findings suggest a key role of ACD in the EtOH
reinforcing effects. In the present paper we review the role of EtOH-derived ACD in the
reinforcing effects of EtOH and the possibility that ACD may serve as a therapeutically
targetable biomarker in the search for novel treatments in alcohol abuse and alcoholism.
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INTRODUCTION
A recurring emergent theory in the alcohol field is that the rein-
forcing properties of alcohol are not produced by the ethanol
(EtOH) molecule itself, but may depend upon the action of
EtOH metabolites/products within the central nervous system
(CNS) (Deitrich, 2004; Quertemont et al., 2005c; Correa et al.,
2012).
This stance proposes EtOH as a pro-drug, and metabolism
of EtOH to acetaldehyde (ACD) within the CNS could mediate
most, if not all, of the CNS effects of EtOH (Quertemont et al.,
2005a). The reinforcing properties of alcohol are most likely gen-
erated through a complex series of peripheral and central effects
of both alcohol and its metabolites. Therefore a better under-
standing for how the metabolites/products of alcohol contribute
to the reinforcing properties of alcohol is important for the devel-
opment of efficacious pharmacotherapies for alcohol abuse and
alcoholism.
BRIEF HISTORY OF ACD AND ALCOHOLISM
ACD, in EtOH addiction, has been classically considered as an
aversive EtOH by-product useful in the pharmacological therapy
of alcoholics (Diana et al., 2003; Suh et al., 2006).
Elevation of ACD peripheral blood levels, after disulfiram
administration causes a number of typical effects, known as
flushing syndrome (Suh et al., 2006) including anxiogenic effects
and endocrine stress responses (Escrig et al., 2012). Over the
last decades, several lines of research have described the aver-
sive effects of alcohol following the ingestion of compounds
which significantly affected alcohol-related behaviors in both
preclinical as well as clinical populations. Hald and Jacobsen
(1948), reported similar aversive symptoms (redness of the
face, increased heart rate, sleepiness, etc.) following treat-
ment with tetraethylthiuramdisulfide and alcohol consump-
tion, thereby suggesting that blocking Aldehyde Dehydrogenase
(ALDH) resulted in a sharp increase in blood levels of ACD,
which in turn, produced an increase in the aversive side effects
of drinking. Tetraethylthiuramdisulfide has since been given
the name disulfiram (marketed as antabuse) and was the first
compound approved for the treatment of alcoholism by the
US FDA.
The primary pharmacological action of disulfiram involves the
enzyme ALDH that is responsible for converting ACD to acetate
in metabolizing EtOH. Disulfiram inhibits ALDH and thus
increases the concentration of ACD. Most of the adverse effects
that characterize alcohol sensitivity were attenuated efficiently by
4-methylpyrazole (4-MP), ADH inhibitor, following ALDH inhi-
bition by both disulfiram and cyanamide (Stowell et al., 1980;
Kupari et al., 1983).
In sharp contrast with this notion, Chevens (1953) observed
that patients don’t have aversive effects by taking low doses of
EtOH when under disulfiram treatment, and it has also been
reported that ALDH inhibitors may potentiate the euphoric and
pleasurable effects of low doses of EtOH (Brown et al., 1983).
Given the clinical implications of the early antabuse
studies, several theories emerged associating alcoholism and
ACD (Carpenter and MacLeod, 1952; Myers and Veale, 1969;
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Davis et al., 1970; Walsh et al., 1970; Griffiths et al., 1974).
The most strident theories suggested that ACD was responsi-
ble for all the effects associated with alcohol and that alco-
holism would be more appropriately termed acetaldehydism
(Walsh et al., 1970; Raskin, 1975).
ETOHMETABOLISM
EtOH is first metabolized into ACD through several enzy-
matic and nonenzymatic mechanisms, the main enzymatic path-
ways being alcohol dehydrogenase (ADH), cytochrome P4502E1
(CYP2E1) and catalase H2O2 system. In the periphery, ACD is
formed from EtOH through the action of ADH primarily in the
liver. In the brain, ADH is inactive (Zimatkin et al., 1998), and
formation of ACD from EtOH is achieved primarily through the
action of another enzyme, catalase H2O2 system (Sippel, 1974;
Zimatkin, 1991).
A prerequisite for the involvement of ACD in EtOH behavioral
effects is the occurrence of pharmacologically significant levels of
ACD in the brain after alcohol consumption.
The levels of ACD in the CNS have profound effects
in mediating the reinforcing actions of EtOH. ACD derived
from the peripheral metabolism of EtOH penetrates from
blood to brain with difficulty because of the metabolic bar-
rier presented by ALDH across the Blood-Brain Barrier (BBB)
(Eriksson and Sippel, 1977; Deitrich, 1987; Zimatkin, 1991; Hunt,
1996; Quertemont and Tambour, 2004). In addition, in the liver
ALDH rapidly converts ACD into acetate and very low levels
of ACD are detected in blood after the administration of mod-
erate doses of EtOH (Quertemont and Tambour, 2004). Further
research indicated that high levels of peripherally administered
ACD results in detection of ACD in the brain within minutes
(Ward et al., 1997). Therefore, peripheral ACD may over saturate
the peripheral ALDH, allowing some percentage of ACD to enter
the brain (Quertemont et al., 2005b). However, this mechanism
does not provide an absolute protection of the brain because high
blood concentrations allow ACD to cross the BBB. Additional
local metabolic pathways (e.g., CYP2E1) can also result in the
formation of ACD from EtOH within the brain (Zakhari, 2006)
and pharmacologically significant amounts of ACD can be gener-
ated in situ thereby producing effects that are difficult to ascribe
to peripheral mechanisms.
A plausible source of ACD in the brain is the in situ synthe-
sis from some of the EtOH that escapes peripheral metabolism.
ACD can be formed in the brain through the peroxidatic activ-
ity of catalase H2O2 system and by oxidation via other oxidizing
enzymes such as CYP2E1.
Indeed, production of ACD during EtOH oxidation in situ
was found and confirmed in several laboratories (Aragon et al.,
1992; Gill et al., 1992; Hamby-Mason et al., 1997; Zimatkin et al.,
1998; Person et al., 2000). Although ADH is not expressed in
the brain (Zimatkin and Buben, 2006; Deitrich, 2011), ACD can
nevertheless be generated by the action of catalase H2O2 sys-
tem and to a minor extent by CYP2E1, both enzymes present in
the brain (Aragon and Amit, 1992; Zimatkin et al., 2006; Deitrich,
2011). In vitro studies indicate that catalase H2O2 system gen-
erates 60 to 70% of brain ACD while CYP2E1 some 15 to 20%
(Zimatkin et al., 2006).
In a study in mice, Correa et al. found that when cata-
lase H2O2 system-mediated metabolism of EtOH into ACD
is blocked (Correa et al., 2008) there is a suppressive effect of
the anxiolytic actions of EtOH (Correa et al., 2008), suggesting
that centrally formed ACD contributes to the anxiolytic effects
of EtOH. Additionally, it has been reported that when cata-
lase H2O2 system activity is pharmacologically reduced, via 3-
aminotriazole (3-AT), rats reduce their intake and preference for
EtOH (Koechling and Amit, 1994), a decreased voluntary EtOH
intake in UChB rats is observed (Tampier et al., 1995) and EtOH-
induced conditioned place preference (CPP) in mice (Font et al.,
2008) is blocked. Furthermore the presence of 3-AT induced
a concentration-dependent reduction of the amount of ACD
generated after incubation. Homogenates of perfused brains of
rats treated with AT or cyanamide (another H2O2-dependent
catalase blocker) also showed a dose-dependent reduction of
ACD (Aragon and Amit, 1992).
Recently, Karahanian et al. (2011) developed lentiviral vec-
tors that coded for an shRNA designed to inhibit the synthe-
sis of catalase H2O2 system. The single stereotaxic administra-
tion of an anticatalase-lentiviral vector into the ventral tegmen-
tal area (VTA), which reduced catalase H2O2 system levels by
70 to 80% (Quintanilla et al., 2012; Tampier et al., 2013), virtu-
ally abolished the voluntary EtOH consumption (up to 95%) by
UChB rats. The lentiviral anticatalase shRNA administration also
abolished the increases in dopamine release in nucleus accumbens
(Acb) induced by the acute administration of EtOH. These effects
strongly support a role of catalase H2O2 system and thus ACD
in the central metabolism and in the motivational properties of
EtOH.
REINFORCING PROPERTIES OF ACD
ACD itself possesses reinforcing properties, which suggests that
some of the behavioral pharmacological effects attributed to
EtOH may be a result of the formation of ACD, supporting the
involvement of ACD in EtOH addiction (Brown et al., 1979).
On this account, the positive reinforcing properties generally
attributed to EtOH may in fact be mediated centrally by its
metabolite. ACD, per se, would then be responsible for many bio-
logical effects which are not clearly distinguishable from those of
EtOH (Quertemont et al., 2005c; Font et al., 2006a,b; Peana et al.,
2008, 2009, 2010b; Correa et al., 2012).
ACD induces CPP in rats after intracerebroventricular admin-
istration (Smith et al., 1984), is self-administered directly into
the cerebral ventricles (Brown et al., 1979) and into the (VTA)
(McBride et al., 2002) whereas Rodd-Henricks et al., (2002)
reported ACD self-administration into VTA in alcohol-preferring
rats.
Further ACD induces positive motivational effects not only
by central administration but also when administered peripher-
ally. In fact, studies have shown that ACD induces CPP in rats
after intraperitoneal administration (Quertemont and De Witte,
2001) and rats self-administer ACD intravenously (Myers et al.,
1984; Takayama and Uyeno, 1985). Importantly, ACD induces
CPP after intragastric administration (Peana et al., 2008), and is
orally self-administered (Peana et al., 2010b) thereby mimicking
the commonly employed route of administration of alcoholic
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beverages in humans. Further, ACD induces conditioned stim-
ulus preference (Quertemont and De Witte, 2001), and directly
enhances the activity of putative dopamine (DA) neurons in the
rat VTA in vivo (Foddai et al., 2004). In addition, blockade of
alcohol dehydrogenase with 4-MP prevents EtOH-induced CPP,
oral EtOH self-administration and stimulation of the mesolim-
bic DA system (Foddai et al., 2004; Melis et al., 2007; Peana et al.,
2008). As 4-MP administration mainly prevents peripheral ACD
formation, thereby reducing ACD available to penetrate the brain
(Isse et al., 2005), and provokes a consequent increase in blood
EtOH levels (Waller et al., 1982), it is possible that the lack of
EtOH-induced CPP could be ascribed to high blood EtOH con-
centrations (Melis et al., 2007). However, reduction of pharmaco-
logically active ACD, by administration of the ACD-sequestering
agent D-penicillamine (DP), which does not increase blood
EtOH concentrations, also prevents spontaneous EtOH drinking
and strongly sustain the hypothesis that some of the behavioral
(Font et al., 2006b) and rewarding (Font et al., 2006a) effects of
EtOH are mediated by ACD.
ACD ACTIONS IN THE VTA
Most abused drugs, including EtOH, stimulate the release of DA
in several limbic regions (Di Chiara, 2002). Therefore, the rein-
forcing properties of ACD may be mediated by increasing the
release of DA in terminal areas.
Through utilization of the intracranial self-administration
(ICSA) paradigm, Rodd-Henricks et al. (2002) established that
rats will readily self-administer ACD directly into the poste-
rior ventral tegmental area (pVTA) at concentrations that were
1000-fold lower than that for EtOH (Rodd-Henricks et al., 2002;
Rodd et al., 2005, 2008). It appears that the pVTA is signifi-
cantly more sensitive to the reinforcing properties of ACD com-
pared to EtOH. Alcohol preferring rats display the highest lev-
els of ICSA for ACD doses that are approximately 2,000-fold
lower than the optimal dose of EtOH (Rodd-Henricks et al.,
2002; Rodd et al., 2005, 2008). Responding/infusion data from the
ICSA experiments exhibit an inverted “U-shaped” dose–response
curve for ACD, in which lower and higher doses do not pro-
duce reliable responding (Rodd-Henricks et al., 2002; Rodd et al.,
2005, 2008), suggesting that the reinforcing effects of ACD
within the pVTA appears to involve activation of DA neurons
(Rodd et al., 2005, 2008). In line with this, Melis et al. (2007)
found that ACD is essential for EtOH-increased microdialysate
DA levels in the Nucleus Accumben shell (AcbSh) and that this
effect is mimicked by intra-VTA ACD administration that pro-
duced an increase in DA release in the AcbSh to 150% that of
baseline.
ACD has excitatory actions on neurons of the VTA as clearly
demonstrated by the effects on DA release and on the firing fre-
quency of individual VTA neurons. In experiments using in vivo
recording methods, ACD was injected intravenously, and a dose-
dependent increase in firing of dopaminergic VTA neurons was
reported (Foddai et al., 2004). Thus, ACD parallels the effects
observed with EtOH, but at 50 times lower concentrations. The
effects of EtOH on VTA neuronal activity were blocked by sys-
temic pretreatment with the ADH inhibitor 4-MP, but this drug
had no effect on ACD induced excitation (Foddai et al., 2004),
suggesting that the excitatory effects of EtOH on the VTA are
mediated by ACD. Sequestration of ACD in vivo by adminis-
tration of DP is sufficient to block the effects of intragastri-
cally administered EtOH or ACD (Enrico et al., 2009). These
key results indicate that ACD-induced activation of dopaminer-
gic VTA neurons mimics EtOH-induced excitation (Diana et al.,
2008), and is produced at much lower concentrations compared
to EtOH (Brodie et al., 1990; Brodie and Appel, 1998). Further-
more, EtOH applied in the presence of a catalase H2O2 system
inhibitor, 3-AT, failed to produce its characteristic excitation of
the VTA. Further, in exploring the mechanism of ACD exci-
tation of VTA neurons, Melis et al. (2007) examined the effect
of ACD on two ion currents, A-current and h-current. An A-
current represents a rapidly-inactivating potassium current that
contributes to spike after hyperpolarization and is involved in
the regulation of firing frequency of dopaminergic VTA neu-
rons (Koyama and Appel, 2006). The authors noted a right-
ward voltage shift produced by ACD on IA (Melis et al., 2007).
Also noted was a significant increase in h-current produced by
acutely applied ACD; this is reminiscent of the effect of EtOH,
which has been shown to acutely increase Ih of VTA neurons
(Brodie and Appel, 1998; Okamoto et al., 2006). The most parsi-
monious explanation suggests that EtOH is metabolized to ACD
by local catalase H2O2 system in the VTA, and the authors of
these studies suggest that, in general, EtOH actions on the VTA
are mediated by ACD (Deehan et al., 2013a,b).
Overall, it seems most likely that ACD is a crucial component
of the overall effects of EtOH on dopaminergic neurons of the
VTA; the essential action of ACD could be parallel to EtOH, or it
could enhance EtOH-induced changes. Blockade of the formation
of ACD can reduce the response of dopaminergic VTA neurons to
EtOH, and could serve as a platform for the development of agents
that reduce the rewarding and reinforcing actions of EtOH.
ACD AS A BIOMARKER
The results reviewed above suggest that enzymatic manipu-
lations of EtOH metabolism would diminish its rewarding
properties, possibly discouraging drinking (Figure 1). There
could be several mechanisms by which reduction of ACD
levels could reduce alcohol intake. For example, advantage
can be obtained by exploiting the ACD-chelating properties
of thiol compounds (Nagasawa et al., 1980). Indeed, adminis-
tration of the ACD-sequestering agent DP, reduces voluntary
EtOH consumption, ACD motivational properties (Font et al.,
2005, 2006b) and free-choice EtOH drinking behavior in mice
(Font et al., 2006a), acting centrally to reduce EtOH-derived
acetaldehyde (Font et al., 2005; Serrano et al., 2007). Further,
L-cysteine, prevented EtOH and ACD-induced conditioned place
preference (Peana et al., 2009), reduced oral EtOH and ACD
self-administration (Peana et al., 2010a, 2012), and blunted both
EtOH and ACD-induced stimulation of DA release in the AcbSh
(Sirca et al., 2011).
In addition, modulation of catalase H2O2 system by enzy-
matic inhibition (Melis et al., 2007), or H2O2 scavenging may
reduce ACD formation in the CNS and the motivational prop-
erties of EtOH (Ledesma et al., 2012; Ledesma and Aragon, 2012,
2013). Since the enzyme catalase takes H2O2, as a co-substrate
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FIGURE 1 | Schematic representation of central and peripheral ethanol
(EtOH) metabolic pathways and possible pharmacological targets. EtOH
is metabolized into acetaldehyde (ACD) through several pathways, the main
enzyme being alcohol dehydrogenase (ADH), inhibited by 4-methylpyrazole
(4-MP); CYP2E1 and catalase H2O2 system inactivated by 3-aminotriazole
(3-AT) an enzymatic inhibitor and by alpha lipoic acid (ALA) a radical scavenger
for H2O2. ACD is subsequently oxidized into acetate by aldehyde
dehydrogenase (ALDH) inhibited by disulfiram. An additional strategy is
represented by sequestration agents of ACD, D-Penicillamine (DP) and
L-Cysteine.
to form compound I, the central production of ACD derived
from the metabolism of EtOH in the brain (Cohen et al., 1980;
Sinet et al., 1980), may be affected by pharmacological manipula-
tion of this system. Accordingly, pretreatment with alpha lipoic
acid, scavenger of H2O2, reduces the acquisition and recondi-
tioning of ethanol-induced CPP in mice (Ledesma and Aragon,
2013) and reduces EtOH self administration in rats (Peana et al.,
2013).
These considerations suggest further experiments to probe the
use of these molecules as potential experimental therapies and
could help in devising new effective pharmacologic treatments in
alcoholism.
CONCLUSIONS
It is hypothesized that many neuropharmacological, neurochem-
ical, neurotoxic, and behavioral effects of EtOH are mediated by
the first metabolite of EtOH, ACD (Hunt, 1996; Deitrich, 2004;
Quertemont and Tambour, 2004; Quertemont et al., 2005b,c;
Zimatkin et al., 2006). In addition, the present observations
suggest that the positive motivational properties following EtOH
administration, and the EtOH-induced enhancement of DAergic
transmission, require EtOH’s first metabolite, ACD.
The important distinction between the central and the periph-
eral effects of ACD lays the groundwork for considering that many
of the central effects of EtOH could in fact be dependent on the
actions of its first metabolite, ACD. Although peripherally accu-
mulated ACD is a potential toxic and deterrent substance, high
levels of this substance can reach the brain and generate positive
effects that can promote later consumption.
At last, targeting ACD, instead of EtOH, may offer new poten-
tial biomarkers in the search for novel compounds to reduce
excessive alcohol intake, abuse and ultimately alcoholism. In gen-
eral, targeting drug metabolism may reveal new ways to treat
addictive disorders not limited to alcohol abuse but possibly use-
ful in other addictions such as tobacco (Pianezza et al., 1998),
heroin and cocaine dependence (Kreek et al., 2005) and other
chemical dependencies (reviewed in Bough et al. (2013) and ref-
erences therein).
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